3rd May 2007 11:59
Oxford Biomedica PLC03 May 2007 For Immediate Release 3 MAY 2007 OXFORD BIOMEDICA ANNUAL GENERAL MEETING 2007 Oxford, UK: 3 May 2007: Oxford BioMedica (LSE: OXB), the leading gene therapycompany, announced today that all resolutions were duly passed at its AnnualGeneral Meeting, held today in London. -Ends- For further information, please contact:Oxford BioMedica plc:Professor Alan Kingsman, Chief Executive Tel: +44 (0)1865 783 000 City/Financial Enquiries:Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Tel: +44 (0)20 7466 5000Buchanan Communications Scientific/Trade Press Enquiries:Gemma Price/ Holly Griffiths/ Katja Stout Tel: +44 (0)20 7268 3002Northbank Communications Notes to editors 1. Oxford BioMedica Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in thedevelopment and commercialisation of novel therapeutic vaccines and gene-basedtherapies with a focus on the areas of oncology and neurotherapy. The Companywas established in 1995 as a spin-out from Oxford University, and is listed onthe London Stock Exchange. The Company has a platform of gene delivery technologies, which are based onhighly engineered viral systems. Oxford BioMedica also has in-house clinical,regulatory and manufacturing know-how. In oncology, the lead product candidateis TroVax(R), an immunotherapy for multiple solid cancers, which is beingdeveloped and commercialised in collaboration with Sanofi-Aventis. TroVax is inPhase III development for renal cancer and Sanofi-Aventis is implementing adevelopment plan for colorectal cancer. Oxford BioMedica's oncology pipelineincludes a specific immunotherapy candidate, Hi-8(R) MEL, for melanoma, whichhas completed two clinical trials. In neurotherapy, the Company's lead product,ProSavin(R), is expected to enter clinical development for Parkinson's diseasein 2007. The neurotherapy pipeline also includes preclinical gene-basedtherapeutics for vision loss, motor neuron disease and nerve repair. Inaddition, the Company has a platform technology for therapeutic vaccines forinfectious diseases. The Company is underpinned by over 80 patent families, which represent one ofthe broadest patent estates in the field. The Company has a staff ofapproximately 75 split between its main facilities in Oxford and its whollyowned subsidiary, BioMedica Inc, in San Diego, California. Corporatepartnerships include the collaboration on TroVax with Sanofi-Aventis and on atargeted antibody therapy with Wyeth. Intervet, Sigma-Aldrich, Viragen, MolMedand Virxsys are also corporate partners. Technology licensees include Merck &Co, Biogen Idec, GlaxoSmithKline and Pfizer. Further information is available at www.oxfordbiomedica.co.uk This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Oxford Biomedica